phase
ii
trial
conduct
subject
human
papillomaviru
hpv
associ
highgrad
cervic
dysplasia
test
safeti
efficaci
microparticl
encapsul
pdna
vaccin
amolimogen
express
cell
epitop
protein
hpv
type
analysi
perform
subset
subject
test
whether
cell
specif
hpv
increas
respons
amolimogen
immun
subject
receiv
amolimogen
elev
cell
respons
hpv
andor
peptid
seven
also
increas
correspond
hpv
andor
peptid
addit
cell
prime
expand
vitro
hpv
peptid
demonstr
crossreact
correspond
hpv
peptid
data
demonstr
treatment
amolimogen
elicit
cell
respons
hpv
human
papilloma
viru
hpv
infect
recogn
primari
risk
factor
develop
cervic
dysplasia
cervic
cancer
differ
genet
subtyp
viru
associ
diseas
progress
highgrad
dysplasia
cervic
cancer
associ
subset
high
risk
viral
type
frequent
type
type
close
relat
subtyp
major
hpv
infect
clear
host
probabl
develop
progress
diseas
significantli
increas
patient
moder
suppress
immun
system
therapeut
vaccin
target
toward
viral
antigen
investig
mean
enhanc
host
immun
respons
hpv
lead
diseas
resolut
type
approach
could
consid
altern
surgic
procedur
current
use
standard
care
hpv
contain
doubl
strand
circular
dna
genom
encod
six
earli
express
gene
two
late
express
gene
protein
form
viral
capsid
express
late
infect
viral
protein
requir
viral
dna
replic
protein
viru
assembl
amplif
viral
genom
upper
layer
epithelium
protein
highrisk
hpv
involv
disregul
cell
cycl
therefor
oncogen
viral
protein
interact
target
protein
degrad
wherea
protein
interfer
normal
function
retinoblastoma
protein
collect
disrupt
normal
cell
cycl
checkpoint
process
protein
requir
maintain
transform
state
repres
potenti
antivir
therapeut
drug
target
anogenit
wart
condylomata
acuminata
caus
sexual
transmit
nononcogen
type
hpv
percentag
global
popul
develop
wart
somewher
rang
approxim
one
million
new
case
year
unit
state
hpv
infect
result
anogenit
wart
caus
hpv
type
although
individu
contract
viru
clear
infect
remain
asymptomat
number
peopl
develop
condyloma
anogenit
wart
life
threaten
howev
neg
physic
mental
impact
affect
diseas
sinc
diseas
resolut
depend
upon
cell
mediat
immun
respons
therapeut
vaccin
prime
expand
hpv
specif
tcell
may
use
treatment
option
patient
diseas
amolimogen
bepiplasmid
formerli
investig
immunotherapeut
contain
cell
epitop
protein
hpv
test
see
front
matter
elsevi
inc
right
reserv
clinic
treatment
high
grade
cervic
dysplasia
amolimogen
consist
plasmid
dna
pdna
vector
encapsul
within
polylactid
coglycolid
plg
microparticl
micron
mean
diamet
microparticl
encapsul
increas
stabil
pdna
vaccin
within
host
protect
pdna
enzymat
cleavag
inject
host
particul
natur
formul
caus
local
inflamm
occur
result
influx
antigen
present
cell
apc
phagocytos
microparticl
plasmid
releas
insid
activ
apc
result
direct
transfect
profession
antigen
present
cell
express
hpv
epitop
context
mhc
class
ii
molecul
lead
cell
prime
expans
amolimogen
test
safeti
efficaci
random
doubleblind
placebo
control
phase
ii
clinic
trial
patient
highgrad
cervic
dysplasia
result
demonstr
favor
safeti
profil
prospect
defin
sub
group
women
year
clinic
resolut
diseas
significantli
higher
amolimogen
treat
individu
compar
placebo
control
group
versu
interest
although
amolimogen
compris
hpv
sequenc
observ
resolut
lesion
could
occur
women
altern
non
hpv
subtyp
amolimogen
design
induc
expand
cell
specif
hpv
antigen
therefor
quantit
analysi
enhanc
hpv
specif
peripher
blood
mononuclear
cell
pbmc
patient
drug
placebo
administr
perform
assess
immunolog
activ
patient
cohort
use
ifnc
elispot
method
detect
peripher
cell
activ
subject
follow
treatment
amolimogen
placebo
control
elispot
assay
abil
detect
low
frequenc
antigen
specif
tcell
peripher
blood
work
report
perform
test
whether
cell
specif
hpv
induc
amolimogen
immun
well
determin
increas
level
cell
specif
non
subtyp
hpv
present
peripher
blood
patient
cohort
immun
addit
object
studi
explor
whether
cell
clone
specif
hpv
peptid
recogn
respond
target
cell
present
correspond
hpv
peptid
although
evalu
studi
presenc
higher
level
cell
specif
altern
hpv
subtyp
may
help
explain
clinic
observ
resolut
diseas
women
non
hpv
subtyp
togeth
effort
may
provid
framework
futur
studi
explor
divers
andor
cross
reactiv
natur
cell
respons
amolimogen
immun
subject
histolog
confirm
highgrad
lesion
cervix
cervic
intraepitheli
neoplasia
iiiii
enrol
institut
review
board
irb
approv
phase
ii
clinic
studi
amolimogen
placebo
salin
administ
subject
via
intramuscular
inject
later
quadricep
inject
occur
week
subject
close
monitor
end
week
trial
point
underw
loop
electrosurg
excis
procedur
leep
describ
previous
subject
enrol
studi
hpv
type
use
residu
sampl
subject
cytolog
evalu
thinprep
system
gynecolog
sampl
collect
use
cytobrushspatula
cervic
sampl
devic
sampl
devic
place
transport
medium
sent
central
lab
analysi
hpv
subtyp
detect
pcr
method
adapt
mano
et
al
brigham
women
hospit
boston
approxim
ml
heparin
venou
blood
sampl
drawn
clinic
site
subject
visit
ship
overnight
ambient
temperatur
central
lab
covanc
laboratori
indianapoli
pbmc
process
pbmc
isol
sediment
ficollpaqu
gradient
amersham
pharmacia
biotech
ab
uppsala
sweden
store
freez
medium
contain
fetal
calf
serum
fc
jrh
bioscienc
lenexa
ks
dmso
sigmaaldrich
st
loui
mo
pbmc
sampl
aliquot
concentr
ml
store
frozen
overnight
transfer
liquid
nitrogen
maintain
vapor
phase
aliquot
pbmc
ship
overnight
dri
ice
eisai
research
institut
lexington
peptid
use
immunolog
assay
acquir
qualiti
control
biochem
inc
hopkinton
neomp
inc
san
diego
ca
lyophil
peptid
minimum
pure
ship
manufactur
eisai
research
institut
peptid
suspend
dimethyl
sulfoxid
dmso
sigma
carlsbad
ca
final
concentr
mgml
pipet
individu
aliquot
peptid
store
day
assay
peptid
select
base
sever
criteria
first
nonam
peptid
sequenc
consid
immunolog
assay
second
candid
peptid
sequenc
preselect
base
hla
bind
restrict
epitop
encod
within
amolimogen
moder
high
affin
bind
properti
consid
measur
competit
radioisotop
label
peptid
bind
assay
data
shown
third
predict
algorithm
use
search
sequenc
homolog
drug
encod
sequenc
hpv
amino
acid
sequenc
posit
cell
receptor
surfac
access
side
chain
posit
nonam
peptid
bound
within
molecul
nine
hpv
peptid
test
total
peptid
group
one
three
peptid
set
tabl
made
least
one
hpv
peptid
correspond
hpv
andor
peptid
pool
peptid
deriv
cytomegaloviru
epstein
barr
viru
influenza
cef
pool
anaspec
san
jose
ca
use
control
elispot
assay
pbmc
sampl
sent
american
red
cross
dedham
hla
type
laboratori
use
labtyp
sso
type
test
one
lambda
inc
canoga
park
ca
method
determin
hla
b
type
patient
follow
method
use
gener
antigen
specif
cell
vitro
day
dendrit
cell
three
donor
puls
llmgtlgiv
nllirclrc
peptid
cocultur
pbmc
match
donor
well
plate
cultur
maintain
day
restimul
prime
peptid
load
onto
autolog
pbmc
day
ngml
ngml
iuml
ad
day
cultur
media
replac
day
day
antigen
specif
cell
harvest
wash
count
test
peptid
reactiv
ifnc
elispot
assay
cell
reactiv
prime
peptid
correspond
hpv
peptid
test
ifnc
elispot
assay
employ
enumer
frequenc
hpv
specif
effector
cell
within
pbmc
popul
assay
design
directli
test
cell
reactiv
previous
describ
reactiv
antigen
specif
cell
gener
vitro
immun
cultur
human
ifnc
elispot
kit
purchas
r
system
inc
minneapoli
mn
step
involv
plate
develop
perform
accord
manufactur
instruct
day
assay
either
cell
enrich
cryopreserv
pbmc
use
tcell
enrich
column
r
system
inc
minneapoli
mn
antigen
specif
cell
ivi
cultur
count
trypan
blue
adjust
concentr
ml
cell
line
serv
apc
elispot
assay
adjust
final
concentr
ml
puls
lgml
peptid
h
co
plate
cell
per
well
neg
control
elispot
well
contain
cell
cell
peptid
posit
control
cell
cell
puls
cef
pool
anaspec
san
jose
ca
assay
set
use
complet
pbmc
medium
rpmi
jrh
lifesci
human
ab
serum
csix
diagnost
germantown
wi
hepe
buffer
life
technolog
grand
island
ny
lglutamin
life
technolog
penicillinstreptomycin
life
technolog
life
technolog
elispot
plate
block
pbmc
medium
min
room
temperatur
block
medium
remov
prior
addit
cell
plate
duplic
test
control
well
set
assay
perform
experi
cell
incub
plate
h
co
plate
develop
per
manufactur
instruct
develop
plate
allow
dri
rt
ship
zellnet
consult
inc
fort
lee
nj
count
via
elispot
reader
system
carl
zeiss
vision
germani
ks
elispot
softwar
respons
peptid
consid
posit
least
spot
form
cell
sfc
per
million
cell
background
subtract
neg
control
cell
cell
alon
posit
respons
treatment
initi
defin
increas
baselin
respons
particular
peptid
peptid
select
base
combin
experiment
determin
bind
affin
molecul
data
shown
potenti
cross
reactiv
predict
sequenc
homolog
put
cell
receptor
contact
residu
base
molecular
model
crystallograph
analysi
cell
complex
shown
tabl
three
peptid
set
contain
least
one
peptid
andor
correspond
hpv
andor
peptid
peptid
store
frozen
day
assay
thaw
peptid
puls
onto
apc
cell
use
stimul
elispot
assay
multicent
doubleblind
random
placebocontrol
phase
ii
trial
conduct
subject
high
grade
cervic
neoplasia
test
safeti
efficaci
amolimogen
result
trial
describ
previous
subject
screen
confirm
diseas
random
three
group
shown
fig
subject
inject
intramuscularli
either
lg
encapsul
pdna
lg
encapsul
pdna
placebo
control
salin
timepoint
week
subject
return
clinic
observ
period
includ
visit
week
immun
respons
analysi
subject
select
phase
ii
clinic
trial
base
hla
type
sampl
avail
pbmc
archiv
subject
assign
random
identifi
number
studi
least
one
pretreat
sampl
one
posttreat
sampl
subject
subject
analysi
sampl
baselin
week
week
week
post
final
immun
week
week
post
final
immun
l
c
e
l
hpv
q
l
c
k
f
hpv
nine
peptid
select
screen
elispot
assay
peptid
nine
amino
acid
length
hpv
peptid
encod
amolimogen
predict
algorithm
use
search
sequenc
homolog
amolimogen
encod
sequenc
hpv
amino
acid
sequenc
posit
highlight
ital
bold
yield
correspond
hpv
peptid
use
studi
fig
provid
pbmc
eight
subject
receiv
lg
dose
subject
receiv
lg
dose
five
subject
receiv
placebo
control
assay
perform
batch
format
timepoint
one
patient
test
day
order
detect
low
frequenc
hpvspecif
cytotox
tlymphocyt
ctl
ifnc
elispot
protocol
includ
cell
enrich
step
prior
plate
use
cell
incub
cell
puls
hpv
peptid
test
recognit
reactiv
antigen
peptid
analysi
enhanc
hpv
specif
tcell
respons
greater
pretreat
valu
detect
subject
receiv
amolimogen
result
subject
increas
hpv
cell
respons
post
baselin
includ
tabl
c
also
list
subject
measur
increas
hpv
immun
tabl
frequenc
hpv
peptid
respons
placebo
control
group
low
howev
note
one
subject
respons
hpv
llmgtlgiv
hpv
lflntlsfv
peptid
low
overal
magnitud
met
criteria
enhanc
respons
subject
increas
hpv
cell
respons
show
increas
least
one
amolimogen
encod
hpv
peptid
week
timepoint
week
final
amolimogen
immun
timepoint
domin
epitop
llmgtlgiv
hpv
lflntlsfv
hpv
subject
respond
respect
tabl
peptid
set
case
cell
respons
lower
detect
week
timepoint
subject
demonstr
enhanc
cell
respons
one
amolimogen
encod
hpv
peptid
seven
show
increas
cell
respons
least
one
correspond
hpv
peptid
tabl
two
subject
respons
highest
magnitud
week
decreas
markedli
week
timepoint
case
respons
hpv
cell
respons
note
cell
respons
detect
subject
higher
patient
test
analysi
magnitud
cell
respons
subject
maintain
week
timepoint
one
subject
placebo
control
group
detect
increas
cell
respons
hpv
set
detect
increas
respons
correspond
hpv
peptid
three
differ
healthi
donor
pbmc
test
cultur
design
prime
expand
cell
specif
hpv
nllirclrc
peptid
day
three
round
peptid
stimul
cell
clone
collect
test
cross
reactiv
abil
recogn
react
correspond
hpv
peptid
shown
fig
cell
prime
hpv
peptid
demonstr
cross
reactiv
properti
donor
respond
hpv
peptid
magnitud
respons
hpv
kvlircylc
peptid
three
case
similar
greater
respons
detect
hpv
prime
peptid
fig
result
demonstr
cell
specif
hpv
peptid
nllirclrc
abl
crossreact
correspond
peptid
kvlircylc
amolimogen
investig
therapeut
vaccin
consist
pdna
encod
antigen
region
protein
hpv
encapsul
biodegrad
plg
microparticl
abil
amolimogen
immun
elicit
cell
recogn
hpv
epitop
well
cell
recogn
respond
restrict
hpv
peptid
contain
homolog
cell
contact
residu
investig
studi
peripher
blood
cell
respons
measur
hpv
subject
cin
enrol
phase
ii
clinic
studi
subject
trial
inject
lg
encapsul
pdna
placebo
control
cell
enrich
subject
pbmc
ifnc
elispot
assay
perform
measur
immun
respons
hpv
peptid
epitop
hpv
peptid
encod
amolimogen
pdna
formul
design
abl
bind
molecul
current
studi
increas
immun
respons
hpv
peptid
detect
subject
immun
amolimogen
regardless
dose
variat
magnitud
respons
peptid
among
subject
howev
consist
timepoint
respons
detect
strongest
respons
detect
week
week
post
third
final
immun
week
effector
cell
respons
decreas
level
near
baselin
week
respons
week
cell
respons
hpv
llmgtlgiv
hpv
lflntlsfv
peptid
highest
magnitud
frequenc
entir
clear
observ
increas
cell
respons
subject
receiv
amolimogen
potenti
explan
insuffici
dose
prime
expand
measur
respons
andor
incorrect
blood
collect
timepoint
restrict
test
pbmc
collect
week
analysi
plausibl
peek
immun
respons
occur
timepoint
far
remov
week
cell
respons
hpv
infect
individu
llmgtlgiv
peptid
well
character
sequenc
use
develop
addit
hpv
immunotherapeut
note
five
placebo
control
subject
test
demonstr
increas
respons
hpv
peptid
low
magnitud
ie
tcell
hpv
type
perform
subject
analysi
chang
hpv
statu
pcr
baselin
visit
five
subject
two
elev
immun
respons
hpv
peptid
set
remain
subject
without
chang
hpv
type
nine
elev
immun
respons
hpv
suggest
elev
immun
respons
like
due
new
hpv
infect
rather
due
immun
amolimogen
next
interest
studi
whether
cell
specif
hpv
type
induc
amolimogen
immuniza
fig
result
vitro
immun
ivi
cultur
cell
gener
pbmc
three
healthi
donor
prime
hpv
peptid
nllirclrc
cell
stimul
prime
peptid
day
day
cell
harvest
test
use
ifnc
elispot
reactiv
prime
peptid
correspond
hpv
peptid
kvlircylc
neg
control
peptid
known
bind
peptid
protein
fldprpltv
peptid
sequenc
list
xaxi
result
report
ifnc
cell
tion
subject
cell
test
abil
recogn
respond
peptid
hpv
hpv
type
associ
genit
wart
hpv
peptid
select
base
sever
criteria
one
includ
predict
algorithm
select
peptid
base
sequenc
homolog
posit
hpv
nonom
peptid
one
mani
six
amino
acid
substitut
increas
cell
respons
hpv
andor
detect
subject
receiv
amolimogen
case
respons
hpv
peptid
respons
hpv
peptid
peak
week
reduc
week
timepoint
data
offer
evid
amolimogen
immun
yield
increas
cell
specif
hpv
subtyp
previous
mention
observ
increas
hpv
tcell
respons
week
one
placebo
control
subject
interestingli
cell
respons
correspond
hpv
peptid
patient
increas
time
result
sfc
week
respect
shown
tabl
correl
exist
cell
gener
hpv
peptid
hpv
peptid
case
subject
detect
increas
cell
respons
hpv
andor
peptid
also
increas
correspond
hpv
andor
peptid
correl
suggest
cell
clone
induc
amolimogen
immun
respond
two
differ
homolog
peptid
one
except
subject
subject
histori
genit
wart
may
explain
detect
respons
hpv
tidqlcktf
peptid
sfc
week
correspond
respons
hpv
klpqlctel
sfc
week
hpv
klpdlctel
sfc
week
peptid
also
shown
tabl
whether
subject
experienc
resolut
diseas
observ
correl
induct
peripher
hpv
immun
respons
peptid
select
studi
cin
iiiii
resolut
previous
report
patient
cin
iii
measur
ctl
respons
hpv
antigen
clear
diseas
one
potenti
explan
observ
regulatori
cell
could
interf
suppress
effector
cell
effect
target
dysplast
tissu
known
regulatori
cell
present
play
key
role
hpv
associ
cervic
lesion
persist
progress
carcinoma
analysi
small
number
trial
subject
design
explor
observ
rather
studi
induct
hpv
cell
respons
cross
reactiv
properti
follow
immun
amolimogen
result
studi
indic
amolimogen
induc
cell
respons
multipl
cell
epitop
phenomenon
well
document
dna
vaccin
enhanc
cell
respons
detect
week
week
final
immun
multipl
restrict
peptid
hpv
cell
respons
direct
toward
hpv
also
reactiv
peptid
hpv
sequenc
homolog
base
data
set
clinic
trial
subject
clear
respons
detect
gener
hpv
specif
cell
cross
react
hpv
epitop
distinct
cell
popul
specif
uniqu
epitop
hpv
initi
experi
test
whether
cell
line
specif
hpv
epitop
encod
amolimogen
pdna
construct
could
react
hpv
epitop
similar
sequenc
homolog
result
demonstr
cell
line
prime
singl
hpv
peptid
recogn
respond
epitop
hpv
offer
evid
suggest
peripher
blood
hpv
cell
expand
amolimogen
immun
capabl
cross
react
hpv
epitop
studi
examin
cross
reactiv
mous
man
kreijtz
et
al
demonstr
consider
abil
season
ctl
specif
influenza
viru
recogn
epitop
avian
influenza
viru
observ
import
assess
potenti
impact
pandem
outbreak
caus
suggest
presenc
cross
reactiv
ctl
may
benefit
gener
popul
anoth
studi
nilg
et
al
show
ctl
reactiv
epitop
tmdlqpet
would
also
recogn
peptid
human
coronaviru
peptid
sequenc
homolog
data
support
notion
cross
reactiv
cell
recogn
immunogen
region
well
region
common
pathogen
work
perform
mccarthi
colleagu
author
show
immun
b
transgen
mice
hpv
dna
yield
cross
reactiv
tcell
recogn
relat
hpv
type
final
work
report
william
et
al
demonstr
cell
line
specif
hpv
gener
unrel
healthi
donor
abil
recogn
respond
altern
hpv
type
observ
cell
capabl
cross
reactiv
offer
potenti
explan
amolimogen
induc
hpv
specif
cell
could
recogn
peptid
epitop
hpv
strain
presenc
cell
mediat
immun
respons
help
clear
hpv
infect
enhanc
number
function
cell
specif
hpv
epitop
within
host
may
provid
clinic
benefit
patient
hpvmediat
diseas
subject
receiv
amolimogen
found
cell
respons
test
restrict
hpv
peptid
either
week
week
timepoint
least
greater
baselin
valu
seven
subject
increas
cell
respons
test
restrict
hpv
peptid
result
demonstr
immun
amolimogen
investig
therapeut
vaccin
base
hpv
sequenc
elicit
cell
respons
also
recogn
hpv
epitop
furthermor
show
cell
line
specif
hpv
peptid
recogn
hpv
peptid
use
studi
data
combin
clinic
observ
diseas
resolut
occur
women
hpv
posit
suggest
addit
studi
design
character
abil
amolimogen
induc
andor
cell
react
hpv
type
would
interest
